Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998

被引:76
作者
Sacchi, CT
Whitney, AM
Popovic, T
Beall, DS
Reeves, MW
Plikaytis, BD
Rosenstein, NE
Perkins, BA
Tondella, MLC
Mayer, LW
机构
[1] Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA
[3] Adolfo Lutz Inst, Dept Bacteriol, Div Med Biol, Sao Paulo, Brazil
关键词
D O I
10.1086/315833
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two hundred eighty-one sporadic Neisseria meningitidis serogroup B isolates, collected through active laboratory-based surveillance, were selected to be analyzed by PorA variable region (VR) typing to determine the prevalence of PorA types in the United States. A substantial number of distinct VR types were identified, 31 in VR1 and 41 in VR2. A total of 73 different PorA types were found, and 76.7% of these types comprise nonprototype sequences in VRI, VR2, or both. The most prevalent PorA types were P1.7,16-20 (previously P1.7,16i), P1.22,14, P1.22-1,14 (previously P1.22a,14), P1.7,16, P1.7-1,1 (previously P1.7d,1), P1.19,15, and P1.17,16-3 (previously P1.B,16d). No correlation was observed between the PorA types and geographic origin of the isolates. These data may aid in the design of an efficacious outer membrane protein-based vaccine by identifying the most appropriate PorA types for vaccine formulation. Studies are needed to fully evaluate the extent of cross-protection in humans among the variants and prototypes in each PorA VR family.
引用
收藏
页码:1169 / 1176
页数:8
相关论文
共 48 条
[1]  
Aase A, 1998, SCAND J IMMUNOL, V47, P388
[2]  
Abdillahi H, 1988, FEMS Microbiol Immunol, V1, P139
[3]   NEISSERIA-MENINGITIDIS GROUP-B SEROSUBTYPING USING MONOCLONAL-ANTIBODIES IN WHOLE-CELL ELISA [J].
ABDILLAHI, H ;
POOLMAN, JT .
MICROBIAL PATHOGENESIS, 1988, 4 (01) :27-32
[4]   Neisseria meningitidis: Vaccines and vaccine candidates [J].
AlaAldeen, DAA ;
Cartwright, KAV .
JOURNAL OF INFECTION, 1996, 33 (03) :153-157
[5]   EFFECT OF OUTER-MEMBRANE VESICLE VACCINE AGAINST GROUP-B MENINGOCOCCAL DISEASE IN NORWAY [J].
BJUNE, G ;
HOIBY, EA ;
GRONNESBY, JK ;
ARNESEN, O ;
HOLSTFREDRIKSEN, J ;
HALSTENSEN, A ;
HOLTEN, E ;
LINDBAK, AK ;
NOKLEBY, H ;
ROSENQVIST, E ;
SOLBERG, LK ;
CLOSS, O ;
ENG, J ;
FROHOLM, LO ;
LYSTAD, A ;
BAKKETEIG, LS ;
HAREIDE, B .
LANCET, 1991, 338 (8775) :1093-1096
[6]   EFFICACY, SAFETY, AND IMMUNOGENICITY OF A MENINGOCOCCAL GROUP-B (15-P1.3) OUTER-MEMBRANE PROTEIN VACCINE IN IQUIQUE, CHILE [J].
BOSLEGO, J ;
GARCIA, J ;
CRUZ, C ;
ZOLLINGER, W ;
BRANDT, B ;
RUIZ, S ;
MARTINEZ, M ;
ARTHUR, J ;
UNDERWOOD, P ;
SILVA, W ;
MORAN, E ;
HANKINS, W ;
GILLY, J ;
MAYS, J .
VACCINE, 1995, 13 (09) :821-829
[7]   Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins [J].
Cartwright, K ;
Morris, R ;
Rümke, H ;
Fox, A ;
Borrow, R ;
Begg, N ;
Richmond, P ;
Poolman, J .
VACCINE, 1999, 17 (20-21) :2612-2619
[8]   Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age [J].
de Kleijn, ED ;
de Groot, R ;
Labadie, J ;
Lafeber, AB ;
van den Dobbelsteen, G ;
van Alphen, L ;
van Dijken, H ;
Kuipers, B ;
van Omme, GW ;
Wala, M ;
Juttmann, R ;
Rümke, HC .
VACCINE, 2000, 18 (15) :1456-1466
[9]  
DEMORAES JC, 1992, LANCET, V340, P1074
[10]   Structural and evolutionary inference from molecular variation in Neisseria porins [J].
Derrick, JP ;
Urwin, R ;
Suker, J ;
Feavers, IM ;
Maiden, MCJ .
INFECTION AND IMMUNITY, 1999, 67 (05) :2406-2413